CALC (CalciMedica) Future 3-5Y EPS without NRI Growth Rate : N/A (As of Apr. 13, 2025)

View and export this data going back to 2020. Start your Free Trial

What is CalciMedica Future 3-5Y EPS without NRI Growth Rate?

Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, CalciMedica's Future 3-5Y EPS without NRI Growth Rate is N/A.

Competitive Comparison of CalciMedica's Future 3-5Y EPS without NRI Growth Rate

For the Biotechnology subindustry, CalciMedica's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CalciMedica's Future 3-5Y EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CalciMedica's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where CalciMedica's Future 3-5Y EPS without NRI Growth Rate falls into.

Save Embed

;

Save Embed

;

CalciMedica (NAS:CALC) Future 3-5Y EPS without NRI Growth Rate Explanation

Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

CalciMedica Future 3-5Y EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of CalciMedica's Future 3-5Y EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

CalciMedica Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CalciMedica Inc (NAS:CALC) » Definitions » Future 3-5Y EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

505 Coast Boulevard South, Suite 307, La Jolla, CA, USA, 92037

Website

https://www.calcimedica.com

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need. Its proprietary technology targets the inhibition of calcium release-activated calcium channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases for which there are no approved therapies.

Executives

Fred A Middleton	director, 10 percent owner	400 SOUTH EL CAMINO REAL STE 1200, SAN MATEO CA 94402-1708
A. Rachel Leheny	director, 10 percent owner, officer: Chief Executive Officer	C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545
Robert N Wilson	director	C/O JOHNSON & JOHNSON, ONE JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Sanderling Venture Partners Vi Co Investment Fund Lp	10 percent owner	1300 S EL CAMINO REAL SUITE 203, SAN MATEO CA 94402
Eric W Roberts	director, 10 percent owner, officer: Chief Business Officer	VALENCE LIFE SCIENCES LLC, 500 PARK AVENUE 9TH FLOOR, NEW YORK NY 10022
Sudarshan Hebbar	officer: Chief Medical Officer	C/O CALCIMEDICA, INC., 505 COAST BOULEVARD SOUTH, LA JOLLA CA 92037
Eric Bjerkholt	director	132 PURDURE AVENUE, KENGSINGTON CA 94708
Sanderling Ventures Vii (canada), L.p.	10 percent owner	1300 S. EL CAMINO REAL, SUITE 203, SAN MATEO CA 94402
Sanderling Ventures Management Vi	10 percent owner	1300 S EL CAMINO REAL SUITE 203, SAN MATEO CA 94402
Sanderling Vi Beteiligungs Gmbh & Co Kg	10 percent owner	1300 S EL CAMINO REAL SUITE 203, SAN MATEO CA 94402
Sanderling Vi Limited Partnership	10 percent owner	1300 S EL CAMINO REAL SUITE 203, SAN MATEO CA 94402
Sanderling Venture Partners Vi Lp	10 percent owner	1300 S EL CAMINO REAL SUITE 203, SAN MATEO CA 94402
Allan Shaw	director	C/O CELSUS THERAPEUTICS PLC, 24 WEST 40TH STREET, NEW YORK NY 10018
Michael J. Dunn	officer: President and COO	C/O CALCIMEDICA, INC., 505 COAST BOULEVARD SOUTH, LA JOLLA CA 92037
Kenneth A. Stauderman	officer: Chief Scientific Officer	C/O CALCIMEDICA, INC., 505 COAST BOULEVARD SOUTH, LA JOLLA CA 92037